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Abstract 
Background 
Lynch syndrome is an autosomal dominant cancer predisposition syndrome caused by 
mutations in the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2. Individuals 
with Lynch syndrome have an increased risk of colorectal cancer, endometrial cancer, 
ovarian and other cancers. Lynch syndrome remains underdiagnosed in the UK. Reflex 
testing for Lynch syndrome in early-onset colorectal cancer patients is proposed as a method 
to identify more families affected by Lynch syndrome and offer surveillance to reduce cancer 
risks, although cost-effectiveness is viewed as a barrier to implementation. The objective of 
this project was to estimate the cost–utility of strategies to identify Lynch syndrome in 
individuals with early-onset colorectal cancer in the NHS. 
Methods 
A decision analytic model was developed which simulated diagnostic and long-term 
outcomes over a lifetime horizon for colorectal cancer patients with and without Lynch 
syndrome and for relatives of those patients. Nine diagnostic strategies were modelled which 
included microsatellite instability (MSI) testing, immunohistochemistry (IHC), BRAF 
mutation testing (methylation testing in a scenario analysis), diagnostic mutation testing and 
Amsterdam II criteria. Biennial colonoscopic surveillance was included for individuals 
diagnosed with Lynch syndrome and accepting surveillance. Prophylactic hysterectomy with 
bilateral salpingo-oophorectomy (H-BSO) was similarly included for women diagnosed with 
Lynch syndrome. Costs from NHS and Personal Social Services perspective and quality-
adjusted life years (QALYs) were estimated and discounted at 3.5% per annum. 
Results 
All strategies included for the identification of Lynch syndrome were cost-effective versus no 
testing. The strategy with the greatest net health benefit was MSI followed by BRAF followed 
by diagnostic genetic testing, costing £5,491 per QALY gained over no testing. The effect of 
prophylactic H-BSO on health-related quality of life (HRQoL) is uncertain and could 
outweigh the health benefits of testing, resulting in overall QALY loss. 
Conclusions 
Reflex testing for Lynch syndrome in early-onset colorectal cancer patients is predicted to be 
a cost-effective use of limited financial resources in England and Wales. Research is 
recommended into the cost-effectiveness of reflex testing for Lynch syndrome in other 
associated cancers and into the impact of prophylactic H-BSO on HRQoL. 
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Background 
Lynch syndrome (LS; previously known as hereditary non-polyposis colorectal cancer, 
HNPCC) is an autosomal-dominant cancer predisposition syndrome caused by mutations in 
the DNA mismatch repair (MMR) genes MLH1, MSH2, MSH6 and PMS2 [1]. LS predisposes 
to colorectal cancer (CRC) as well as extracolonic cancers including endometrial cancer and 
ovarian cancer (see Table 1). 
Table 1 Cumulative risk to age 70 of selected Lynch syndrome associated cancers 
Cancer Risk to age 70 (95% CI) 
Colorectal cancer (men) 38% (25%–59%) 
Colorectal cancer (women) 31% (19%–50%) 
Endometrial cancer (women) 33% (16%–57%) 
Ovarian cancer (women) 9% (4%–31%) 
Source: Bonadona et al. [45]. 
Notes: Estimates do not include PMS2 mutation carriers. 
Cancer prevention strategies can be employed for individuals with LS which benefit both 
individuals already affected by cancer and also those unaffected, yet LS remains 
underdiagnosed in the UK, in which there is no universal systematic testing for LS. 
The National Institute for Health Research Health Technology Assessment Programme was 
asked to commission research into the cost-effectiveness of systematic testing for LS in 
individuals with newly diagnosed early-onset CRC and here we report the results of that 
research. 
Diagnosis 
The diagnosis of LS rests on the results of microscopic and molecular tests. Microsatellite 
instability (MSI) in tumour tissue indicates a loss of MMR proficiency, while 
immunohistochemistry (IHC) of MMR proteins can indicate loss of their expression in a 
tumour; both indicate LS as a possible cause of the tumour. Sporadic tumours with MSI or 
lack of MMR protein expression also occur, so adjunctive tests such as for the BRAF V600E 
mutation and hypermethylation of the MLH1 promotor can reduce false-positive results. 
Although LS can be strongly suspected on the basis of personal and family history (such as 
the Amsterdam II criteria and revised Bethesda criteria) [1] allied with the results of tumour 
testing, ideally the finding of a pathogenic mutation in one of the DNA MMR genes is 
necessary for a firm diagnosis. The current standard for diagnostic testing for MMR 
mutations is DNA sequencing (to detect point mutations and small insertions/deletions) and 
multiplex ligation-dependent probe amplification (MLPA; to detect large structural DNA 
abnormalities). The finding of a pathogenic mutation is a prerequisite for predictive testing of 
relatives. 
The interpretation of a mutation as pathogenic is complex and not always possible, although a 
significant recent advance has been made with a standardised classification scheme [2]. 
To avoid psychological harm, the genetic testing of individuals for constitutional mutations 
responsible for a cancer predisposition syndrome should only take place after informed 
consent and genetic counselling [3]. 
There are thousands of unique MMR DNA variants, although a proportion of these (around 
11%) are not pathogenic or likely not pathogenic and a proportion (around 32%) have 
unknown significance (i.e., could be pathogenic but not confirmed) [2]. Screening for MMR 
mutations in unaffected individuals (i.e., in the general population) is generally thought to be 
prohibitively expensive and ill-advised due to the prevalence of variants of unknown 
significance and the lack of evidence regarding the psychological impact of such results. 
Screening is therefore reserved for individuals thought likely to have LS. 
Management 
If LS is identified in an individual, surveillance can be offered to reduce the risk of CRC. UK 
guidelines state that “Total colonic surveillance (at least biennial) should commence at age 25 
years. […] Surveillance should continue to age 70–75 years or until comorbidity makes it 
clinically inappropriate.” [4] High quality data from randomised trials is not available 
regarding the effectiveness of colonoscopic surveillance, but the best available published 
evidence suggests a 62% reduction in the risk of CRC for individuals with LS undergoing 3-
yearly colonoscopy in Finland [5,6]. Despite the evidence showing that colorectal 
surveillance is effective in LS, recent work shows that there is poor compliance in the UK 
with international guidelines, with inadequate assessment and wide variability in the 
management of LS [7]. 
Evidence is lacking to support prophylactic surgery to prevent CRC or the practice of 
aggressive surgery (removing significantly more of the colorectum than necessary for 
treatment alone) for CRC, although the latter is recommended in the BSG/ACPGBI 
guidelines [4]. Likewise evidence is lacking to support surveillance for gynaecological 
cancers yet this too is recommended in guidelines [6]. There is evidence to support 
prophylactic surgery (H-BSO) to prevent gynaecological cancers [8], although impact on 
health-related quality of life (HRQoL) has not been assessed; guidelines have not 
recommended prophylactic surgery but have suggested it be presented as an option [6]. 
Recommendations are also made regarding surveillance for other cancers associated with LS, 
but without supporting evidence [6]. 
Objective 
To estimate the cost–utility of strategies to identify LS in early-onset CRC (aged under 50 
years) in the NHS in England and Wales. 
Methods 
We developed a decision analytic model in consultation with clinical experts (co-author Dr 
Ian Frayling; acknowledged contributors Mr Ian Daniels, Dr Carole Brewer and Mr John 
Renninson, all of Royal Devon & Exeter NHS Trust) and parameterised using the best 
available data relevant to the NHS. 
Population 
Individuals in England and Wales newly diagnosed with CRC aged under 50 years (denoted 
probands) and their relatives, who would be offered predictive genetic testing if a LS 
mutation was found in a proband. 
Interventions 
Nine diagnostic strategies for LS were chosen on the basis of the tests available, strategies in 
previous cost-effectiveness models and expert advice. Due to the lack of clearly defined 
current practice, two strategies were included in which genetic testing is not offered; in the 
first of these no attempt was made to identify LS in the probands, and in the second the 
Amsterdam II criteria were used. The final set of strategies was: 
1. Strategies without genetic testing 
1(1). No testing at all (all diagnosed LS negative) 
2(2). Amsterdam II criteria for diagnosis 
2. IHC four-panel test for MLH1, MSH2, MSH6 and PMS2, followed by mutation testing if 
IHC result abnormal 
3. IHC four-panel test, followed by BRAF V600E mutation testing if MLH1 abnormal and 
mutation testing if MMR protein other than MLH1 abnormal or BRAF V600E mutation not 
found 
4. MSI testing, followed by mutation testing if MSI found 
5. MSI testing, followed by BRAF V600E mutation testing if MSI found, followed by 
mutation testing if BRAF V600E mutation not found 
6. As Strategy 0 but IHC performed in parallel with mutation testing to aid interpretation 
(i.e., not used diagnostically) 
7. IHC four-panel test followed by mutation testing if IHC result abnormal. If IHC result 
normal, follow Strategy 0 
8. Direct mutation testing 
Mutation testing for LS includes both sequencing and MLPA. Probands would be classified 
as LS positive if a mutation was found or LS assumed if no mutation was found but LS was 
suspected on the basis of family history. In addition probands could decline genetic 
counselling or diagnostic genetic testing and in this case would be classified as LS assumed 
or LS negative on the basis of family history. 
When LS mutations were found in probands, testing was offered to their first-degree relatives 
(FDRs). Where the family mutation was also found in those FDRs, cascade testing was used 
to reach more distant relatives. When probands were assumed to have LS, only their FDRs 
were assumed to have Lynch syndrome. 
Individuals classified as LS positive or LS assumed would be offered biennial colonoscopic 
surveillance commencing at age 25 and ending at age 75. 
Outcomes 
The primary outcomes were the expected total costs and quality-adjusted life years (QALYs) 
for each diagnostic strategy, the incremental cost-effectiveness ratios (ICERs) of the 
strategies and the incremental net health benefit (INHB) of the strategies at a willingness-to-
pay of £20,000 per QALY. 
Secondary outcomes were the diagnostic test accuracies of the strategies, the expected 
number of colonoscopies and cancers in each strategy, and the life expectancy in each 
strategy. 
Study design 
We developed a decision analytic model with two components. 
The first component (the diagnostic submodel) consisted of a decision tree and was used to 
estimate the number of probands and relatives who would receive each possible diagnosis 
and to estimate how many individuals diagnosed with Lynch syndrome would accept 
colonoscopic surveillance for each of the strategies listed in Interventions (above). It also 
calculated the cost of diagnosis in each strategy. 
The second component (the management submodel) consisted of an individual patient 
simulation and was used to estimate the lifetime costs that would be incurred through 
colonoscopies, CRC treatment, hysterectomies (note these also include bilateral salpingo-
oophorectomy) and endometrial cancer treatment and the life years and QALYs that would 
be accrued for individuals with each diagnosis. 
The results of the two submodels were combined to give a full incremental analysis of costs 
and QALYs [9]. 
The management submodel included a number of possible events: colonoscopy, colonoscopy 
complication, colonoscopy mortality, CRC incidence, metachronous CRC incidence, CRC 
mortality, prophylactic hysterectomy, prophylactic hysterectomy mortality, endometrial 
cancer incidence, endometrial cancer mortality and general mortality. These events 
determined the costs incurred and life years and QALYs accrued. 
In line with the NICE reference case [10], the perspective of NHS and Personal Social 
Services was adopted and costs and benefits were discounted by 3.5% per annum. Costs were 
converted to pounds sterling (£) using purchasing power parities [11] (where appropriate) and 
adjusted to 2013/14 prices using the Hospital and Community Health Services (HCHS) index 
[12]. Individuals were simulated up to age 100 or until death. 
Parameters relating to the natural histories of diseases, the effectiveness of interventions and 
the impact on HRQoL of diseases and interventions were sourced, where possible, from 
national statistics and published literature. Where such values were not available, estimates 
were sought from clinical experts, with priority given to clinical data. 
If data permitted, diagnostic test accuracy parameters were estimated according to previous 
tests, e.g., separate estimates of the test accuracy of BRAF V600E mutation testing were used 
depending on whether IHC or MSI was the preceding test. In some cases such estimates were 
not available and it was necessary to assume the independence of diagnostic tests. 
Colonoscopy was estimated to reduce the incidence of index CRC (i.e., the first incident CRC 
in an individual) using a hazard ratio of 0.387 estimated from a Finnish cohort study [5]. 
Surveillance colonoscopy was estimated to reduce the incidence of metachronous CRC (i.e., 
a subsequent incident CRC) using a hazard ratio of 0.533 estimated from an Italian cohort 
study [13]. Individuals were assumed to develop a maximum of two CRCs over a lifetime. 
Colonoscopies were received every three years in the Finnish cohort study [5] but occur 
every two years in our decision model. The effectiveness of biennial colonoscopy may 
therefore be underestimated and we adjusted the cost of colonoscopies down by a third to 
remove this bias (but keep true representations of the number of colonoscopies and the 
associated risks). Colonoscopies were received every two years in the Italian cohort study 
[13] but the same cost (reduced by a third) was used for colonoscopies intended to prevent 
metachronous CRC, which would bias cost-effectiveness in favour of interventions. 
Sensitivity analyses investigated the effect of colonoscopies being more costly and of 
surveillance being less effective. 
General population norms for HRQoL were included based on Ara and Brazier [14]. No 
disutility was assumed for individuals with CRC unless they had metastatic cancer [15] 
(Dukes’ stage D), in which case a disutility of 0.13 was applied [16]. Colonoscopy was 
assumed not to affect HRQoL. Different types of colorectal surgery were modelled but no 
HRQoL difference was included in the base case [17]. No disutility was assumed for 
endometrial cancer as most patients would be diagnosed with early stage cancer [8] and a 
study of 264 women found HRQoL was similar for early stage endometrial cancer patients as 
for those in the general population [18]. No disutility was assumed for prophylactic H-BSO 
as it is not offered until childbearing would be expected to be completed. Disutilities were 
applied to account for the psychological impact of genetic testing on HRQoL for four months 
[19]. 
Additional file 1 gives further details about our modelling approach for interested readers and 
to allow completion of the CHEERS checklist [20] in Additional file 2. 
Additional file 3: Tables S1 and S2 detail and give sources for the model parameters of the 
diagnostic and management components respectively. 
Results 
Base case results 
All strategies except Strategies 1(2) (family history only) and 8 (direct mutation testing) had 
specificity over 99.5% in relation to probands. All strategies except Strategy 1(2) had 
sensitivity of 60% or greater. Strategy 3 had the highest positive predictive value (98.7%) and 
Strategy 7 had the highest negative predictive value (97.8%). The use of BRAF V600E testing 
in strategies improved specificity without compromising sensitivity. 
Table 2 gives the cost–utility results in the base case and these are shown on the cost–utility 
plane in Figure 1. Secondary outcomes across strategies are given in Table 3. 
Table 2 Base case results representing an annual cohort from England (primary 
outcomes) 
Strategy 1(2) 2 3 4 5 6 7 8
Incremental costs vs Strategy 1(1) [£ Thousands] 
Diagnosis 48.9 662.7 578.5 599.6 586.0 636.9 1061.6 1336.6 
CRC prevention 396.7 735.9 726.9 822.1 817.1 817.1 928.8 1065.7
CRC treatment −249.3 −646.9 −646.2 −725.5 −725.2 −725.2 −814.0 −848.8 
EC prevention 210.4 338.1 333.2 377.3 374.5 374.5 427.0 499.6 
EC treatment −21.7 −60.6 −60.6 −68.0 −68.0 −68.0 −76.2 −78.7 
Total 384.9 1029.2 931.8 1005.4 984.5 1035.3 1527.1 1974.5
Incremental QALYs vs Strategy 1(1) 
Short-term 0 −4.3 −4.1 −4.8 −4.6 −4.6 −5.5 −8.5 
Long-term 63.9 164.0 163.9 184.0 183.9 183.9 206.4 214.8 
Total 63.9 159.7 159.8 179.2 179.3 179.3 200.9 206.3
Cost–utility 
ICER vs Strategy 1(1) [cost per QALY gained] £6021 £6444 £5831 £5610 £5491 £5774 £7601 £9571 
ICER [cost per QALY gained] ED D ED D £5491 D £25106 £82962
INHB at WTP £20000/QALY vs 1(1) [QALYs] 44.7 108.3 113.2 129.0 130.1 127.5 124.5 107.6 
Key: D, dominated; EC, endometrial cancer; ED, extended dominated; WTP, willingness-to-pay. 
Figure 1 Cost–utility plane (base case results, representing an annual cohort from England). 
  
Table 3 Base case results representing an annual cohort from England (secondary 
outcomes) 
Strategy 1(2) 2 3 4 5 6 7 8
Number of colonoscopies vs Strategy 1(1) (=4162) +1618 +3044 +3008 +3401 +3381 +3381 +3842 +4400 
Life expectancy of index patient vs Strategy 1(1) (=13.82 years) +0.06 +0.10 +0.10 +0.12 +0.12 +0.12 +0.13 +0.14 
Life expectancy of index patient with LS vs Strategy 1(1) (=12.93 years) +0.72 +1.24 +1.24 +1.39 +1.39 +1.39 +1.56 +1.61 
Life expectancy of relative vs Strategy 1(1) (=37.38 years) +0.01 +0.05 +0.05 +0.05 +0.05 +0.05 +0.06 +0.06 
Life expectancy of relative with LS vs Strategy 1(1) (=33.97 years) +0.31 +1.24 +1.24 +1.39 +1.39 +1.39 +1.56 +1.61 
Expected number of CRCs vs Strategy 1(1) (=664.9) −8.36 −24.59 −24.56 −27.59 −27.57 −27.57 −30.95 −32.30
Expected number of ECs vs Strategy 1(1) (=53.8) −4.99 −14.29 −14.29 −16.03 −16.03 −16.03 −17.97 −18.55
Abbreviations: EC, endometrial cancer. 
Total discounted costs (across the population for an annual cohort) ranged from £36.22 m for 
Strategy 1(1) to £38.20 m for Strategy 8. The use of BRAF V600E testing reduced total 
discounted costs as savings were made in the number of diagnostic genetic tests. 
Total discounted QALYs (across the population for an annual cohort) ranged from 151,793 
for Strategy 1(1) to 152,000 for Strategy 8. The use of BRAF V600E testing slightly 
improved total discounted QALYs (<0.1 QALYs across population). 
Strategies 2, 4 and 6 were dominated by (i.e., were more costly and less effective than) 
another strategy. Strategies 1(2) and 3 were extended dominated, i.e., were more costly and 
less effective than some combination of other strategies. Strategies 1(1), 5, 7 and 8 were 
therefore on the cost-effectiveness frontier (neither dominated nor extended dominated), as 
shown in Figure 1. The ICER of Strategy 8 versus Strategy 7 was £82,962/QALY, 
substantially greater than the UK cost-effectiveness threshold of £20,000 per QALY, 
suggesting that direct reflex mutation testing is not cost-effective in early-onset CRC patients. 
At a willingness-to-pay of £20,000 per QALY, Strategy 5 resulted in the greatest net health 
benefit (in which costs are converted to QALY losses and offset against QALY gains) of 
130.1 QALYs versus Strategy 1(1). Compared to Strategy 1(1), all strategies had an ICER 
under £10,000/QALY and are therefore considered cost-effective versus no testing. 
Scenario analyses 
We conducted scenario analyses investigating the impact of altering the inclusion age range 
for reflex testing for LS and of replacing BRAF testing with MLH1 methylation testing. We 
also conducted univariate sensitivity analyses on a number of parameters. 
Expanding the inclusion age range 
We explored the impact of increasing the inclusion age from 50 years to 60 years and to 70 
years. A number of parameters were altered for consistency, most notable of these being: the 
number of probands offered reflex testing was increased from 1,699 in the base case to 5,018 
and 13,900 as CRC patients aged under 60 and 70 years respectively are included; the 
prevalence of LS in the probands was reduced from 8.4% in the base case to 5.7% and 3.8%. 
In both scenarios Strategy 5 remained the most cost-effective strategy at a willingness-to-pay 
of £20,000 per QALY (Table 4). In both scenarios there was little difference in QALY gain 
between Strategy 7 and Strategy 8 but there were significant cost increases associated with 
Strategy 8 which suggest universal reflex mutation testing would definitely not be cost-
effective in older CRC patients. Strategy 5 remained cost-effective even when the cost of 
colonoscopies was doubled which suggests these results are fairly robust. 
Table 4 Cost–utility when age limit is raised to 60 and 70 years (representing an annual 
cohort from England) 
Scenario Base case (CRC under 50 years) CRC under 60 years CRC under 70 years
Incremental costs of Strategy 5 vs Strategy 1(1) [£ Thousands] 
Diagnosis 586.0 1590.5 4132.2 
CRC prevention 817.1 1630.3 2990.5 
CRC treatment −725.2 −1450.7 −2604.6 
EC prevention 374.5 772.5 1430.4 
EC treatment −68.0 −139.2 −247.9 
Total 984.5 2403.4 5700.5 
Incremental QALYs Strategy 5 vs Strategy 1(1)
Short-term −4.6 −9.5 −18.1 
Long-term 183.9 322.4 574.4 
Total 179.3 312.9 556.3 
Cost–utility of Strategy 5 vs Strategy 1(1) 
ICER [cost per QALY gained] £5491 £7681 £10247 
INHB at WTP £20,000/QALY [QALYs] 130.1 192.8 271.3 
Abbreviations: EC, endometrial cancer; WTP, willingness-to-pay. 
The INHB obtained when an age limit of 70 years was used exceeded the INHBs for age 
limits of 50 and 60 years due to the increased population size. On average less benefit would 
be accrued for each individual (and more CRC patients without LS would be subjected to 
some amount of testing), but in aggregate results suggest an age limit of 70 years is cost-
effective. 
Replacing BRAF mutation testing with MLH1 hypermethylation testing 
MLH1 promotor hypermethylation causes microsatellite instability and can masquerade as LS 
[21]. The detection of MLH1 promotor hypermethylation can be used to rule out LS unless 
other risk factors are present (e.g., early-onset CRC, family history). 
We conducted a scenario analysis in which BRAF testing in strategies was replaced by 
methylation testing. We found that in this scenario ICERs versus Strategy 1(1) did not change 
significantly from in the base case, but there were small changes to costs and QALYs which 
changed the strategies on the cost-effectiveness frontier. In this scenario Strategy 4 now gives 
more QALYs than Strategy 5 (and remains more expensive) and is therefore no longer 
dominated. Strategy 4 in fact now gives the greatest INHB at a willingness-to-pay of £20,000 
per QALY (129.0 QALYs), although this is still lower than the INHB of Strategy 5 in the 
base case, which suggests that methylation testing may not be as cost-effective as BRAF 
testing, although the difference (if there is one) is likely to be small. 
Univariate sensitivity analyses 
We conducted univariate sensitivity analyses on the majority of parameters (results are 
presented as tornado diagrams in Additional file 1). Strategy 5 remained cost-effective versus 
Strategy 1(1) in all sensitivity analyses except when prophylactic H-BSO was assumed to 
reduce utility by 0.1, in which case Strategy 1(1) (no testing) dominated all strategies, i.e., it 
was the least costly and gave the most QALYs. Strategy 8 (direct mutation testing) was found 
to be cost-effective when the costs of mutation tests for probands were halved – this gives an 
indication that as costs of mutation testing decrease (including through next generation 
sequencing), tumour-based tests IHC, MSI and BRAF V600E may no longer be necessary for 
cost-effective diagnosis. Notably, another sensitivity analysis suggested that reflex testing 
remains cost-effective even when no relatives are identified for testing, with an ICER of 
£6,725/QALY (higher than the £5,491/QALY base case with five relatives identified but still 
below the £20,000/QALY cost-effectiveness threshold). The relative robustness of our results 
to this parameter is due to the inclusion of significant risk-reducing measures for 
metachronous cancer (colorectal and endometrial) in the proband and because we find that 
testing in relatives leads to increased costs as well as improved outcomes. 
Impact on colonoscopy services 
If Strategy 5 were introduced in England, we project that the number of surveillance 
colonoscopies would increase until a steady state of approximately 3,250 surveillance 
colonoscopies would be conducted per year, with an initial growth rate of approximately 120 
surveillance colonoscopies per year (Figure 2). The steady state corresponds to approximately 
two surveillance colonoscopies for each proband tested per year with an initial growth rate of 
approximately one surveillance colonoscopy for each 14 probands tested. These projections 
are based on the assumptions of no demographic or epidemiological changes. 
Figure 2 Projected number of surveillance colonoscopies if Strategy 5 were to be introduced 
in England. 
For example, a district general hospital serving a population of 400,000 would expect to 
reach a steady state of approximately 25 surveillance colonoscopies per year, with an initial 
growth rate of approximately one colonoscopy per year. This would probably be a small 
impact on colonoscopy services compared to interventions such as the NHS Bowel Cancer 
Screening Programme, for which approximately 1,000 colonoscopies are conducted each 
week in the UK [22], corresponding to approximately 300 colonoscopies per year for the 
hypothetical district general hospital. 
A number needed to treat calculation suggests that approximately 90 additional 
colonoscopies would be needed to prevent one CRC if Strategy 5 were to be introduced. 
Colonoscopies also identify CRCs in early stages, thereby improving survival. The 
combination of these and other factors suggest 4–5 colonoscopies would be needed to save 
one life year, and 6 colonoscopies would be needed to save one QALY. 
Discussion 
Relation to previous findings 
There are no comparable studies in the NHS but others have evaluated the cost-effectiveness 
of strategies to identify LS elsewhere. These have generally adopted a similar approach to 
ours – the identification of LS in early-onset CRC patients and in their relatives. Our results 
are broadly consistent with those of others that age-targeted testing for LS with preliminary 
tests before diagnostic mutation testing is cost-effective versus no testing [23-28]. There is 
some disagreement whether direct diagnostic mutation testing would be cost-effective versus 
no testing, but all studies agree that it would not be cost-effective versus strategies with 
preliminary tests. Our results also suggested that reflex testing would be cost-effective even if 
relatives cannot be identified for testing, while some previous analyses have identified this as 
a very sensitive parameter for cost-effectiveness [25-28]. Some of these failed to include any 
potential direct benefits to probands in terms of prevention of metachronous cancer [25,26]. 
Dinh, Rosner et al. considered the approach of general population screening using a risk 
prediction tool (PREMM126) [29] in primary care with a comparator arm of “current practice” 
and found that screening individuals at various ages with a predicted risk of carrying LS of 
5% or greater was cost-effective [30]. It is not clear whether such a strategy would be cost-
effective versus systematic reflex testing as proposed in this analysis, since current practice 
was assumed to include low awareness of Lynch syndrome and limited availability of IHC 
and MSI. While the approach of Dinh, Rosner et al. could result in faster identification of 
families with Lynch syndrome than reflex testing of CRC patients, it would also entail a 
significant and possibly disruptive burden on primary care when initiated, which also may not 
have been costed in their analysis. 
Strengths and limitations 
We did not include costs of surveillance for gynaecological cancer, although this has been 
recommended in clinical guidance [31], because we did not find evidence of the effectiveness 
of such surveillance, and clinical opinion we have sought suggests it is not effective at 
identifying ovarian cancer and not always used in practice. Given that this surveillance can be 
costly (estimated at over $350 per year [32]), it would seem prudent to evaluate the 
effectiveness and cost-effectiveness of gynaecological surveillance before recommending it 
to women with LS, particularly as it may displace prophylactic surgery which has been 
shown to be effective in preventing gynaecological cancers [8]. 
We have not modelled ovarian cancer or other cancers associated with LS. Ovarian cancer 
affects fewer individuals with LS than CRC or endometrial cancer [33] but is associated with 
poor survival [34], so it is likely that failure to model ovarian cancer underestimates the 
benefits of prophylactic bilateral salpingo-oophorectomy (which is already modelled as a cost 
for endometrial cancer prevention) and in this respect our analysis underestimates the cost-
effectiveness of testing for LS. The risks of other cancers associated with LS are highly 
uncertain and it is not clear whether risk-reducing measures such as surveillance are effective 
or could be cost-effective for these cancers. 
We have not included chemoprevention in our analysis, although recent developments 
suggest that chemoprevention may have a role in the management of individuals with LS 
[31], with the CAPP2 study strongly suggesting a reduction in the risk of associated cancers 
in individuals with LS due to long-term aspirin [35] and the Petals trial designed to 
investigate the effectiveness of LNG-IUS in preventing endometrial cancer in individuals 
with LS [36]. These are low cost interventions which would very likely be cost-effective if 
clinical benefit is confirmed and quantified. 
When considering the generalizability of our analysis it is important to consider infrastructure 
requirements to ensure that testing is completed and the results used appropriately. While 
much of this infrastructure already exists in the UK (particularly for testing) there may be 
local variation in follow-up and surveillance after diagnosis. 
Areas of uncertainty 
Uncertainty exists regarding the impact of prophylactic H-BSO on HRQoL; in a sensitivity 
analysis this was found to have a drastic effect on cost–utility (since it is offered to so many 
individuals in the population), resulting in Strategy 1(1) (no testing) being less costly and 
more effective than all others. If it is thought that a disutility of 0.1 is plausible, studies 
should be conducted to estimate the true impact on HRQoL as a priority. We note that the 
best source for utility values following hysterectomy identified in a recent economic study 
[37] involving hysterectomy (in this case for menorrhagia) was a Finnish study using EQ-5D 
to compare the levonorgestrel-releasing intrauterine system (LNG-IUS) with hysterectomy 
over five years [38]. Participants randomised to hysterectomy in this study had an average 
“EQ-5D index” of 0.88 five years after randomisation. While the EQ-5D index is not a 
preference-based utility value (it is instead a regression model mapping EQ-5D states to EQ-
5D VAS measurements), it is scaled 0–1 and the Finnish female population appears to 
measure at 0.91 for ages 35–44 and 0.89 for ages 45–54 [39], which suggests that the long-
term disutility of hysterectomy is likely to be small. It may be possible that the addition of 
bilateral salpingo-oophorectomy results in reduced HRQoL which is not measured by 
Hurskainen et al. since only 7/109 participants received bilateral salpingo-oophorectomy and 
results for these participants are not presented separately [38]. 
Other considerations 
Next generation sequencing may lead to significant cost reductions in mutation testing for 
LS, meaning that in the future direct mutation testing may be cost-effective. In the past there 
have been concerns that direct mutation testing could lead to significant psychological harms 
but recent improvements in the classification of variants of uncertain significance in LS [2] 
and the encouraging interim results from the Mainstreaming Cancer Genetics programme 
[40] could result in a shift towards direct mutation testing for hereditary cancer syndromes 
such as LS. 
A very recent development in tumour testing for LS is the use of IHC to detect BRAF V600E 
mutations, the performance of which has been demonstrated to varying degrees [41,42]. If 
sufficient diagnostic performance can be obtained from this test it may be possible to perform 
sensitive and specific tumour-based testing for LS purely using IHC and avoiding the cost of 
molecular genetic tests. 
Microsatellite instability has been shown to be predictive of the efficacy of fluorouracil-based 
adjuvant chemotherapy [43], which has led to suggestions that MMR proficiency should be 
evaluated in all CRC patients who might receive adjuvant chemotherapy (Stage II and 
above). If testing for MMR proficiency becomes widespread then the incremental cost of 
testing for LS will decrease (since some tumour-based testing will already have been 
conducted for many patients). 
Conclusions 
The results presented suggest that reflex testing for LS would be a cost-effective use of 
limited NHS resources and in the base case of testing in newly-diagnosed CRC patients aged 
under 50 years would not create an excessive additional burden for colonoscopy services. As 
cost-effectiveness may be a perceived barrier to the introduction of reflex testing, these 
results may result in national policy change. 
Maximum net health benefit was estimated to be obtained when all newly-diagnosed CRC 
patients aged under 70 years are tested. Reflex testing remained cost-effective even when the 
cost of colonoscopies (one of the most sensitive parameters) was doubled, which suggests 
there is some robustness in this conclusion. Decision makers will likely want to consider all 
sources of uncertainty and also consider budget impact and the impact on colonoscopy 
services of any policy changes. 
We recommend further research to establish whether it is cost-effective to perform reflex 
testing in other LS-associated cancers (such as endometrial and ovarian cancer). We also 
recommend a controlled study of HRQoL in women following prophylactic H-BSO using the 
EQ-5D tool to ensure that this does not lead to an overall loss of QALYs. We further 
recommend that the effectiveness of gynaecological surveillance for endometrial and ovarian 
cancer in women with LS is evaluated. 
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